Brokerages have cut the company's FY16 earnings estimates between 16% and 29% with target prices too coming down to the Rs 700-800 band
The rap from both the US and UK drug regulators, including the latest one from the latter, has hit the scrip.
This is not just a Ranbaxy or Wockhardt problem, says K Satish Reddy
Sun Pharma and Dr Reddy's top list in terms of those who face most class-action litigation
If the operating principle is that all members of a family must be given an equal role in the business and that they will not make way for better managers who are not members of the family (in other words, the feudal principle), it is hard to see such a company prospering for long in a competitive market.
He has already spearheaded eight significant acquisitions within and outside the country
Cipla tops pharma rankings with 5.42% market share, ahead of Ranbaxy and GSK.
The feud over Ranbaxy patriarch Bhai Mohan Singh's will deepened as Malvinder and Shivender duo (owners of Ranbaxy and Fortis respectively) and Manjit Singh issuing separate notices to the biggest beneficiary, Analjit Singh.
An International Policy Network report in 2010 found that seven per cent of drugs bought from wholesale traders were substandard, and 3.6 per cent of the drugs from traders contained no active ingredient whatsoever.
The weakness in the stock was because of inspections by the American drug regulator at its Halol plant in Gujarat which resulted in eight observations, as well as a downward revision of speciality drug payoffs.
An out-of-court settlement of the feud over Ranbaxy founder Bhai Mohan Singh's will is seemingly imminent between Analjit Singh and Malvinder, Shivender duo, the present promoters of Ranbaxy and Fortis respectively.
Lalit Ahluwalia, CFO, Ranbaxy North America, presents his views on the Indian Budget 2009 at Asia Society in New York.
The US Food and Drug Administration (FDA) says it does not follow an India agenda.
I would focus on R&D, correct or fine tune the US strategy and look at inorganic growth routes
Dilip Shanghvi founded Sun Pharma in 1983.
Currently, the govt directly caps prices of 348 formulations at the average price of all medicines in a particular segment with at least 1% market share
Drug major Sun Pharmaceutical Industries has acquired US-based Pharmalucence Inc for an undisclosed amount.
Take the rediff business quiz and see how much you know about India's pharmaceutical industry.
With local companies facing stress in domestic operations, valuations are down.
Many say trend could lead to concerns on manufacturing quality in Indian facilities.
National Pharmaceutical Pricing Authority names Cipla, Dr Reddy's Labs and Ranbaxy among those.
Finance Minister P Chidambaram has asked the Income Tax department to focus on the companies that pay less than effective tax rate of 24 per cent.
Face NPPA fine for overcharging on anti-asthma drug
Entering Iran may lead to trouble for those having significant presence in the US market.
From promoters losing their firms to consumers realising there are no free lunches, 2019 was a year of getting real,says Shailesh Dobhal.
At close, the Sensex was up 0.7% or 124 points at 18,789 and the Nifty gained 0.8% or 46 points to end at 5,565.
Not far back, in 2010, SRL Diagnostics, promoted by former Ranbaxy promoters Malvinder and Shivinder Singh, acquired the diagnostic services business of Piramal Healthcare for Rs 600 crore (Rs 6 billion).
As Wal-Mart's disclosures on lobbying generated political heat in India, records with American House of Representatives show that around 27 Indian companies have spent money on lobbying in the US.
Disappointed with past experience, domestic majors even skip giving any memorandum.
Ballooning debt forces more and more Indian promoters to sell out to global majors and PE players.
This helps consumers check the authenticity of drugs simply by sending SMSes.
Indian firms raised the money via external commercial borrowings.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances